Company / SG&A per Share
Vaxcyte, Inc. SG&A per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.95
FY2025
5-year range
$0.49 / $0.95
FY2021-FY2025
Trend
+24.8%
vs FY2024
Sector context
#127 of 210
Health Care
What the data says
At $0.95, Vaxcyte, Inc.'s sg&a per share ranks #84 of 210 in the Health Care sector. SG&A per Share has increased for 4 consecutive years, from $0.49 in FY2021 to $0.95 in FY2025.
Based on SEC 10-K filings.
0.95 in FY2025 with a 5-year CAGR of +11.9%.
Increased from $0.62 to $0.95 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +15.7%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Sector benchmark
#84 of 210 in Health CareTop 40% of 210This company $0.95 Sector average $40.75
▼
-97.7% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s sg&a per share has grown for 4 consecutive years.
- In FY2025, sg&a per share increased 24.8% year-over-year.
- Ranks #127 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.95 | +24.8% |
| FY2024 | $0.76 | +21.9% |
| FY2023 | $0.62 | +1.8% |
| FY2022 | $0.61 | +26.1% |
| FY2021 | $0.49 | -10.3% |
| FY2020 | $0.54 | -75.9% |
| FY2019 | $2.25 | +51.7% |
| FY2018 | $1.48 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026